Legal notices

Informations légales

1. Présentation du site

Conformément aux dispositions des Articles 6-III et 19 de la Loi n°2004-575 du 21 juin 2004 pour la Confiance dans l’économie numérique, dite L.C.E.N., il est porté à la connaissance des utilisateurs du site https://rhu-shiva.com/ les présentes mentions légales.


Propriétaire : RHU SHIVA – Bordeaux Population Health (BPH) Center – inserm U1219 ; Université de Bordeaux ; 146 rue Léo Saignat 33076 BORDEAUX Cedex

Créateur : Qwetle (Léo COUFFINHAL et Quentin RAVET)

Responsable publication : Pr Stéphanie Debette (coordinatrice du projet RHU SHIVA) et Pr Thierry Couffinhal (co-coordonnateur du projet RHU SHIVA)

Contact Publication : Equipe de Gestion RHU SHIVA (rhu-shiva@u-bordeaux.fr)

Webmaster : Léo COUFFINHAL – leo.couffinhal@qwetle.fr

Hébergeur : OVH – 2 rue Kellermann – 59100 Roubaix – France


La connexion et/ou la navigation sur le site rhu-shiva.com par l’utilisateur implique acceptation intégrale et sans réserve des présentes mentions légales.

Ces dernières sont accessibles sur le site à la rubrique « Mentions légales ».

2. Conditions générales d’utilisation du site et des services proposés

L’utilisation du site rhu-shiva.com implique l’acceptation pleine et entière des conditions générales d’utilisation ci-après décrites. Ces conditions d’utilisation sont susceptibles d’être modifiées ou complétées à tout moment, les utilisateurs du site rhu-shiva.com sont donc invités à les consulter de manière régulière.
Ce site est normalement accessible à tout moment aux utilisateurs. Une interruption pour raison de maintenance technique peut être toutefois décidée par le RHU SHIVA, qui s’efforcera alors de communiquer préalablement aux utilisateurs les dates et heures de l’intervention.
Le site rhu-shiva.com est mis à jour régulièrement par Qwetle.

3. Description des services fournis.

Le site rhu-shiva.com a pour objet de fournir une information concernant l’ensemble des activités du Consortium du projet de Recherche Hospitalo-Universitaire SHIVA.
Le RHU SHIVA s’efforce de fournir sur son site des informations aussi précises que possible. Toutefois, il ne pourra être tenu responsable des omissions, des inexactitudes et des carences dans la mise à jour, qu’elles soient de son fait ou du fait des tiers partenaires qui lui fournissent ces informations.

Toutes les informations indiquées sur le site rhu-shiva.com sont données à titre indicatif, et sont susceptibles d’évoluer. Par ailleurs, les renseignements figurant sur le site rhu-shiva.com ne sont pas exhaustifs. Ils sont donnés sous réserve de modifications ayant été apportées depuis leur mise en ligne.

4. Limitations contractuelles sur les données techniques.

Le site utilise la technologie JavaScript.
Le RHU SHIVA ne pourra être tenu responsable de dommages matériels liés à l’utilisation du site. De plus, l’utilisateur du site s’engage à accéder au site en utilisant un matériel récent, ne contenant pas de virus et avec un navigateur de dernière génération mis-à-jour.

5. Propriété intellectuelle et contrefaçons.

Le RHU SHIVA est propriétaire des droits de propriété intellectuelle ou détient les droits d’usage sur tous les éléments accessibles sur le site, notamment les textes, images, graphismes, logo, icônes, sons, logiciels.

Qwetle cède au RHU SHIVA les droits d’auteur pour les créations graphiques présentes sur le site rhu-shiva.com pour la durée légale du droit d’exploitation. Toutefois les visuels mis à disposition ne sauraient faire l’objet d’une quelconque modification de la part des exploitants sans l’accord préalable de Qwetle.

Qwetle n’est en rien responsable de l’usage qui pourrait découler de l’exploitation des visuels présent sur le site rhu-shiva.com si ces derniers devaient être utilisés dans un cadre différent.

Le contenu photographique présenté sur le site rhu-shiva.com a été acheté par Qwetle et est utilisé sous licence de Shutterstock.com.

Les photographies des membres du Consortium SHIVA appartiennent à leurs propriétaires. Un accord d’affichage a été demandé au préalable, la reproduction totale ou partielle de ces photos est interdite.

Par ailleurs, toute personne physique a le droit de s’opposer à ce que des données à caractère personnel la concernant fassent l’objet d’un traitement (article 21 du RGPD) en adressant une demande au contact RHU SHIVA.


Toute reproduction, représentation, modification, publication, adaptation de tout ou partie des éléments du site, quel que soit le moyen ou le procédé utilisé, est interdite, sauf autorisation écrite préalable du RHU SHIVA.
Toute exploitation non autorisée du site ou de l’un des éléments qu’il contient sera considérée comme constitutive d’une contrefaçon et poursuivie conformément aux dispositions des articles L.335-2 et suivants du Code de Propriété Intellectuelle.

Le service de cartographie présenté sur le site rhu-shiva.fr est proposé par Openstreetmap. OpenStreetMap® est un ensemble de données ouvertes, disponibles sous la licence libre Open Data Commons Open Database License (ODbL) accordée par la Fondation OpenStreetMap (OSMF).

6. Limitations de responsabilité.

Le RHU SHIVA ne pourra être tenu responsable des dommages directs et indirects causés au matériel de l’utilisateur, lors de l’accès au site rhu-shiva.com, et résultant soit de l’utilisation d’un matériel ne répondant pas aux spécifications indiquées au point 4, soit de l’apparition d’un bug ou d’une incompatibilité.
Le RHU SHIVA ne pourra également être tenu responsable des dommages indirects (tels par exemple qu’une perte de marché ou perte d’une chance) consécutifs à l’utilisation du site rhu-shiva.com.
Des espaces interactifs (possibilité de poser des questions dans l’espace contact) sont à la disposition des utilisateurs. Le RHU SHIVA se réserve le droit de supprimer, sans mise en demeure préalable, tout contenu déposé dans cet espace qui contreviendrait à la législation applicable en France, en particulier aux dispositions relatives à la protection des données. Le cas échéant, le RHU SHIVA se réserve également la possibilité de mettre en cause la responsabilité civile et/ou pénale de l’utilisateur, notamment en cas de message à caractère raciste, injurieux, diffamant, ou pornographique, quel que soit le support utilisé (texte, photographie…).

7. Gestion des données personnelles.

En France, les données personnelles sont notamment protégées par la loi Informatique et Libertés n° 78-87 du 6 janvier 1978, la loi n° 2004-801 du 6 août 2004, l’article L. 226-13 du Code pénal et la Directive Européenne du 24 octobre 1995, le règlement nᵒ 2016/679, dit règlement général sur la protection des données (RGPD), règlement de l’Union européenne qui constitue le texte de référence en matière de protection des données à caractère personnel.

Les données personnelles ne sont collectées qu’après consentement obligatoire de l’utilisateur. Ce consentement est valablement recueilli (boutons et cases à cocher), libre, clair et sans équivoque.


A l’occasion de l’utilisation du site rhu-shiva.com, peuvent être recueillies : l’URL des liens par l’intermédiaire desquels l’utilisateur a accédé au site rhu-shiva.com, le fournisseur d’accès de l’utilisateur, l’adresse de protocole Internet (IP) de l’utilisateur.
En tout état de cause le RHU SHIVA ne collecte des informations personnelles relatives à l’utilisateur que pour le besoin de certains services proposés par le site rhu-shiva.com. L’utilisateur fournit ces informations en toute connaissance de cause, notamment lorsqu’il procède par lui-même à leur saisie dans le formulaire de contact. Il est alors précisé à l’utilisateur du site rhu-shiva.com l’obligation ou non de fournir ces informations.


Conformément aux dispositions des articles 38 et suivants de la loi 78-17 du 6 janvier 1978 relative à l’informatique, aux fichiers et aux libertés, tout utilisateur dispose d’un droit d’accès, de rectification et d’opposition aux données personnelles le concernant, en effectuant sa demande écrite et signée à l’équipe de gestion de SHIVA, accompagnée d’une copie du titre d’identité avec signature du titulaire de la pièce, en précisant l’adresse à laquelle la réponse doit être envoyée.
Aucune information personnelle de l’utilisateur du site rhu-shiva.com n’est publiée à l’insu de l’utilisateur, échangée, transférée, cédée ou vendue sur un support quelconque à des tiers.
Les bases de données sont protégées par les dispositions de la loi du 1er juillet 1998 transposant la directive 96/9 du 11 mars 1996 relative à la protection juridique des bases de données.

Tout utilisateur dispose du droit d’introduire une réclamation auprès de la Commission National de l’Informatique et des Libertés (CNIL, https://www.cnil.fr).

8. Liens hypertextes et cookies.

Le site rhu-shiva.com contient un certain nombre de liens hypertextes vers d’autres sites, mis en place avec l’autorisation du RHU SHIVA. Cependant, le RHU SHIVA n’a pas la possibilité de vérifier le contenu des sites ainsi visités, et n’assumera en conséquence aucune responsabilité de ce fait.

La navigation sur le site rhu-shiva.com est susceptible de provoquer l’installation de cookie(s) sur l’ordinateur de l’utilisateur. Un cookie est un fichier de petite taille, qui ne permet pas l’identification de l’utilisateur, mais qui enregistre des informations relatives à la navigation d’un ordinateur sur un site. Les données ainsi obtenues, après validation et consentement de l’utilisateur, visent à faciliter la navigation ultérieure sur le site. Les cookies ont également vocation à permettre diverses mesures de fréquentation du site internet.

Les données « web analytics » sont collectées de forme anonyme (en enregistrant des adresses IP anonymes) par Google Analytics, et nous permettent de mesurer l’audience de notre site web, les consultations et les éventuelles erreurs afin d’améliorer constamment l’expérience des utilisateurs. Ces données sont utilisées par le Consortium du projet RHU SHIVA et ne seront jamais cédées à un tiers ni utilisées à d’autres fins que celles détaillées ci-dessus.

Le refus d’installation d’un cookie peut entraîner l’impossibilité d’accéder à certains services. L’utilisateur peut toutefois configurer son ordinateur, pour refuser l’installation des cookies. Pour plus d’informations sur les modalités de réglage en fonction de votre navigateur, nous vous invitons à visiter le site https://www.cnil.fr.

9. Droit applicable et attribution de juridiction.

Tout litige en relation avec l’utilisation du site rhu-shiva.com est soumis au droit français. Il est fait attribution exclusive de juridiction aux tribunaux compétents de Paris.

10. Les principales lois concernées.

Loi n° 78-17 du 6 janvier 1978, notamment modifiée par la loi n° 2004-801 du 6 août 2004 relative à l’informatique, aux fichiers et aux libertés.
Loi n° 2004-575 du 21 juin 2004 pour la confiance dans l’économie numérique.

11. Lexique.

Utilisateur : Internaute se connectant, utilisant le site susnommé.
Informations personnelles : « les informations qui permettent, sous quelque forme que ce soit, directement ou non, l’identification des personnes physiques auxquelles elles s’appliquent » (article 4 de la loi n° 78-17 du 6 janvier 1978).


pictogramme partenaires

X. LEVECQ

Xavier Levecq

Chief Technical Officer, Imagine Eyes

Xavier Levecq contributes boundless creativity in the development of Imagine Eyes’ products. Before the inception of Imagine Eyes, he also cofounded Imagine Optic together with Samuel Bucourt and designed new wavefront sensors devices - now recognized worldwide as the reference for optical metrology - that propelled their venture into an international success.

Earlier, recruited by CILAS-EADS while still at university, Xavier developed high-tech optronic systems for « StarWars » military applications based on advanced space optics technologies. Now author of more than 30 patents, Xavier graduated from the Institut d’Optique Graduate School in 1993.

N. CHATEAU

Nicolas CHATEAU

Chief Executive Officer, Imagine Eyes

Nicolas Chateau, PhD, has built his career on bringing innovative ophthalmic products to market. He has driven Imagine Eyes to commercialize the rtx1 retinal camera, a breakthrough imaging device that allows doctors to examine the back of the eye with cellular resolution.

Since he cofounded the company in 2003, Nicolas has established strong partnerships with leading academic and clinical centers, and secured several millions Euros in governmental and European funding. Previously, he worked at developing new high-tech optical products for major companies including Coherent, Ocular Sciences and Essilor.

Author of 12 patents and dozens of scientific publications, Nicolas received his PhD in physics from the University of Paris in 1993 after graduating from the Institut d’Optique Graduate School in 1988.

F. CRIVELLO

Fabrice Crivello

Research Director, UMR 5293 Center

Fabrice Crivello is research director at the CEA. His works are at the interface between methodology in neuroimaging and research in cognitive neuroimaging and neuroepidemiology. 

Following university studies in signal and image processing, he joined the GIN in 1993. Within the SHFJ in Orsay, he obtained a PhD in biological and medical engineering on the detection of cerebral activations with PET. At the Cyceron center in Caen, he completed a post-doctoral internship aiming at building a multi-scale and multi-modality cerebral imaging database. In 1998, he was recruited as a research officer at the CEA and obtained his authorization to conduct research in March 2006. Since 2011 he has been assigned to Bordeaux, where, he and the GIN, have joined the IMN in 2016.

His research is structured along two complementary axes. The first concerns the development, implementation and distribution of automated procedures dedicated to the extraction of structural cerebral phenotypes. The second one concerns the study of these phenotypes in the context of the exploitation of large cerebral imaging cohorts in order to :

  • characterize cerebral anatomical asymmetries, their factors of variability and their genetic determinant;
  • map the maturation and aging of cerebral anatomy.

T.Couffinhal

Thierry COUFFINHAL

SHIVA Co-coordinator, WP3 Leader, Cardiologist

Thierry Couffinhal is Professor of Cardiology and head of the clinical unit of the CEPTA, «Exploration, Prevention and Care Center for Atherosclerosis ». This Unit is dedicated to exploration, prevention and long-term treatment and management of atherosclerotic diseases (angina and myocardial infarction, stroke, peripheral arterial disease) and primary prevention in high-risk patients. Explorations are based on non-invasive up-to-date echographic and other vascular tools. Management is based on a multidisciplinary approach integrating large therapeutic education programs.

Thierry Couffinhal currently participates in many industrial or academic clinical research programs. has been at the head of an Inserm Unit (French Institute of Health and Medical Research) since 2007. The laboratory explores the role of major signaling pathways (Wnt / Hedgehog / JAK2) in vascular biology and thrombosis during development and diseases.

In the last 5 years, he obtained grants from the Fondation Recherche Médicale (FRM), the Agence Nationale de la Recherche (ANR), the Fédération Française de Cardiologie, the health ministry (Programme hospitalier de recherche clinique - PHRC), the Aquitaine Region. He is a member of Société Française de Cardiologie, Société Française d’Angiogenèse and has served on the Scientific Council of the University of Bordeaux (2007-2013). He is also a partner in the European consortium EVGN “European Vascular Genomic Network”, FP6 (2005-2010).

S. Debette

Stéphanie DEBETTE

SHIVA Coordinator, WP6 Leader, Neurologist

Stéphanie Debette is a PUPH in epidemiology/public health at the University of Bordeaux (INSERM U1219, Bordeaux Population Health research center) where she leads a genetic and integrative epidemiology team on neurological and vascular diseases, and a neurologist at Bordeaux University Hospital. Her research focuses on the genetic and environmental determinants of stroke, MRI markers of brain aging, small vessel disease, and cognition.

Since 2004, she has initiated and coordinated the international CADISP consortium on genetic and environmental risk factors for cervical artery dissection and stroke in young subjects. She chaired the International Stroke Genetics consortium between 2017 and 2019, is a member of the scientific committee of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and sits on the board of directors of the World Stroke Organization. She is co-author of 200 papers, including first or last author in Nat Genet, Lancet Neurol, BMJ. She has been awarded an ERC Starting Grant and coordinates the JPND-BRIDGET project on (epi-)genetic determinants of MRI markers of brain aging.

Since the end of 2019 she is principal investigator of the RHU SHIVA project (Stopping cognitive decline and dementia by fighting covert cerebral small vessel disease). She is also a partner in the H2020 COSTREAM (shared mechanisms between stroke and Alzheimer's disease) and PRESTIGE-AF projects. In 2016 she was awarded with the Fondation Claude Pompidou prize for her research on Alzheimer's disease and in 2019 with the European Stroke Organization's prize for scientific excellence in stroke research. Since 2015, she has initiated and co-organised the Neurepiomics summer school on neuroepidemiology in the age of high-speed technologies, in collaboration with Boston University and Kyoto University. A former Fulbright and Bettencourt-Schueller fellow at the Framingham Heart Study, she was also an adjunct associate professor at Boston University and a visiting professor at the Center for Genomic Medicine at Kyoto University.

She is currently also Vice-President in charge of external relations at the University of Bordeaux and a member of the University Council of the LMU University in Munich.

R. Thiebaut

Rodolphe THIEBAUT

Deputy Director of BPH Center UMR1219

Rodolphe Thiebaut is a medical doctor, with specialization in Public Health. He holds a PhD in Biostatistics from Bordeaux University.

He started his research carrier at the Institut National de Sante et de la Recherche Medicale (INSERM) as a research scientist between 2002 and 2009 and as research director between 2010 and 2013. He has been a research fellow in the Immunobiology Division of the Institute of Child Health (London, UK) in 2007.

He is now Professor in Public Health / Biostatistics at the University of Bordeaux. He leads a research group (SISTM - Statistics in Systems Biology and Translational Medicine) devoted to the modelling and analysis of high-dimensional data mainly applied to immunology through the French Vaccine Research Institute (http://www.vaccine-research-institute.fr/en/). This group, which is embedded in the INSERM U1219 Research Centre (http://www.bordeaux-population-health.center/), has been recognized as an INRIA project team since January 2015 (http://www.inria.fr/equipes/sistm). Its translational research starts with immunological questions and ends with the development of statistical methods for the collection and analysis of high-dimensional datasets generated in this domain.

He is in charge of the medical information department of the Bordeaux University Hospital. He is also the Director of the Department of research in Public Health of the Bordeaux University, the deputy director of the INSERM U1219 Research Centre (11 research teams) and the Director of the Graduate School of Digital Public Health, coordinator of the Master of Public Health Data Science at ISPED (Institut de Santé Publique d’Epidémiologie et de Dévelopement). He is the author/co-author of more than 300 publications in peer-reviewed journals including the New England Journal of Medicine, Lancet, AIDS, Journal of Immunology, Biometrics, Biostatistics, Statistics in Medicine, Plos Computational Biology.

P. Boutinaud

Philippe BOUTINAUD

Biomedical Chief Technical Officer, Fealinx

Philippe Boutinaud is currently Technical and Innovation Director of the Fealinx Group (turnover: €11M, 70 employees). He obtained his PhD in Computer Science in 1993 at the University of Paris Sud and then began an industrial career in the world of PLM (Product Lifecycle Management) and digital simulation at SDRC (Structural Dynamic Research Corporation) as an R&D engineer and then head of a software development team. In 1999, he took part in the creation of the Cadesis company, which became Fealinx.

His field of technical and scientific expertise includes governance, specification and software engineering on development projects in the fields of PLM, KM (Knowledge Management), CAD (Computer Aided Design), digital simulation and finally data management and machine learning in biomedical imaging. He was the industrial leader of four CIFRE theses carried out at Fealinx, was the coordinator of the ANR ISemantec project (ANR-06-TLOG-0018), coordinator of the ANR BIOMIST project (ANR-13-CORD-0007) and is the co-director of the LABCOM Ginesislab (ANR 16-LCV2-0006-01).

M. Pâques

Michel PAQUES

Ophtalmologist, 15-20 ophthalmology hospital

Michel Paques is an ophthalmologist and manages a multidisciplinar high-resolution imaging platform for the eye at the Quinze-Vingts hospital (pariseyeimaging.com). With his team of physicists, computer scientists and biologists, he has developed innovative technologies in particular to observe vessels both in terms of their morphology and blood flow.

M. Joliot

Marc JOLIOT

Research Director, UMR 5293 Center

Marc Joliot, Ph.D. is a senior researcher in multimodal biomedical imaging at the French Atomic Energy Commission (CEA) in the “Groupe d’Imagerie Neurofonctionnelle” of  “Institut des maladie neurodégénératives” UMR5293

Specialist in multimodal imaging, acquisition and cohort processing in brain imaging, his primary focus is on intrinsic connectivity observed in functional MRI in the resting state.  The second focus is on the development of new methodology in the analysis and management of bio-imaging data such as AAL (11K citation index) and the AICHA atlas, or resting network classification algorithm (MICCA).

Since 2012 he has developed in collaboration with the company Fealinx, a research axis on the management and processing of imaging data. This collaboration led to the creation in 2017 of a joint laboratory, Ginesislab (LABCOM ANR), whose research focuses on the application of learning and prediction methods using deep learning to imaging cohorts.

J. Korobelnik

Jean-François KOROBELNIK

Ophtalmologist, Bordeaux Hospital

Jean-François KOROBELNIK is professor of ophthalmology at the Bordeaux University Hospital since 1999, Head of Department since May 2013. He is involved in the Research focusing on the epidemiology of eye diseases (Consortium E3), on macula disorders. The care concerns retinal diseases treated medically or surgically (AMD, Retinal detachment, Membrane and macular hole...).

He is a member of the French Society of Ophtalmology (President from May 2013 to May 2015), the American Academy of Ophtalmology, the Association for Research in Vision and Ophtalmology, the American Society of Retina Specialists, Euretina, the Club Francophone des Spécialistes de la Rétine (President from May 2017 to May 2019) and the Club Jules Gonin (Executive committee member).

I. Bourdel-Marchasson

Isabelle BOURDEL-MARCHASSON

Gerontologist, Bordeaux Hospital

Isabelle Bourdel-Marchasson is professor of geriatric medicine since 2002 at the University of Bordeaux (UB). She received her MD from UB and qualified in geriatrics, internal medicine and endocrinology. She also received her PhD in the Center of Magnetic resonance in biological systems (CRMSB), after a master in nutrition.

Since 1990, she is medical practitioner in geriatric medicine at CHU of Bordeaux. She is the head of a post-emergency acute care geriatric unit and of the outpatient hospital dedicated to comprehensive gerontological assessment in frail older patients.

She is chair of the graduation program in geriatrics in Nouvelle Aquitaine and at the Island of Reunion and she drives an e-learning diploma of geriatric medicine.

Prevention of loss of functional independence is a priority to Prof Bourdel-Marchasson accross clinical, teaching and research activities. She has been PI of several randomized clinical trials of non-drug interventions in malnutrition, diabetes and cancer in the older. She is particularly involved in the field of diabetes in the older at an international level. She chairs the Special Interest Group Diabetes from EUGMS (https://www.eugms.org/research-cooperation/special-interest-groups/diabetes.html) and she belongs to the European Diabetes in Older People Working Party (http://diabetesfrail.org).

H. Jacqmin-Gadda

Hélène JACQMIN-GADDA

Research Director, BPH Center UMR1219

Dr Hélène Jacqmin-Gadda, PhD, born in 1968, defended her thesis in 1993 and is a researcher in biostatistics at Inserm since 1996. She is Research Director of the Biostatistics team at the Inserm U1219 Bordeaux Population Health Centre since 1994.

Her main work is focused on the development of models for the analysis of longitudinal data and the occurrence of events in order to study the natural history, risk factors and progression of dementia in the elderly, especially in Alzheimer's disease and cognitive ageing.

The aim of her models is to take into account the characteristics of the disease and the tools for measuring cognition, as well as selection biases that may be particularly important in cohorts of elderly subjects. She is the author of more than 100 publications and co-author of the book "Dynamical Biostatistical Models".

F. Tison

François TISON

Neurologist, Bordeaux Hospital

François Tison (PU-PH, >260 publications, H-Index WOS: 53) is Professor of Neurology at Bordeaux University and consultant neurologist at the University Hospital of Bordeaux. He is coordinator of the Bordeaux Center of Excellence for Neurodegenerative disorders (BIND, https://bind.u-bordeaux.fr/en/), head of the Institute of Neurodegenerative Diseases-clinical branch (IMNc, http://www.imnc-bordeaux.org/) and deputy director of the Institute for Neurodegenerative Diseases (IMN, CNRS UMR 5293- http://www.imn-bordeaux.org/).

He conducted his clinical and research career in the field of neurodegenerative diseases by exploring several disciplines from basic, clinical and translational research to epidemiology. He is PI on multiple academic, industry or foundation-sponsored clinical research studies on neurodegenerative disease. His current interest is focused on non-drug therapies based on the mindfulness in neurodegenerative diseases.

D. Tregouët

David-Alexandre TREGOUËT

WP2 Leader, Research Director, UMR1219

Born 27/01/1973, David-Alexandre Trégouët was recruited at INSERM as a research associate 2nd class in 1999 just after completing his PhD in statistical genetics.

Promoted 1st class Research Director in 2019, his expertise covers the developments and the applications of statistical and bioinformatics methodologies to disentangle the molecular epidemiology of cardiovascular diseases, with a strong focus on venous thromboembolism.

From 2014 to 2018, he has been heading the department of Genomics and Pathophysiology of Cardiovascular Diseases within the INSERM UMR_S 1166 at the ICAN Institute for Cardiometabolism and Nutrition on the Pitié-Salpêtrière Campus (Paris). His team was then composed of clinicians, molecular and cellular biologists, epidemiologists, statistical geneticists and bioinformaticians.

By the middle of 2018, he joined the Bordeaux Population Research Center (https://www.bordeaux-population-health.center/en/) to develop a research program on precision medicine in thrombotic disorders.

C. Longo Dos Santos

Clarisse LONGO DOS SANTOS

VP Clinical Operations, Qynapse

Dr. Clarisse Longo dos Santos, PhD, co-founder and VP of Product Management of Qynapse, is responsible for the tasks related to the development and use of the products, and is involved in the clinical validation of the medical device and the contact with partners.

She obtained her PhD in 2010, at Concordia University, Canada, using fMRI ; she has conducted post-doctoral research at Neurospin/CEA using diffusion MRI in neurological diseases.

She has worked at the CATI platform performing imaging analyses in data from patients with Alzheimer's disease before co-founding Qynapse. Her expertise is in neuroimaging, neuropsychology & clinical studies.

C. Delcourt

Cécile DELCOURT

Research Director, BPH Center UMR1219

Cécile Delcourt has a PhD in statistics and public health and is senior researcher at Inserm U1219-Bordeaux Population Health Research Center, where she leads the LEHA (Lifelong Exposures, Health and Aging) research group.

She has a strong expertise in the epidemiology of eye diseases (in particular AMD, cataract and glaucoma). She is internationally renowned in the identification of risk factors for major eye diseases (in particular smoking, light exposure and nutrition).

She has been leading 2 major population-based epidemiological studies in the field, since 1995 (POLA and Alienor studies). She has founded and led from 2011 to 2018 the “European Eye Epidemiology” consortium, gathering 32 teams from 12 European countries, and is workpackage leader in two European projects (Eye-Risk and Sense-Cog), granted in the Horizon 2020 framework.

B. Mazoyer

Bernard MAZOYER

WP1 Leader, Neuroradiologist UMR5293

Bernard Mazoyer is a professor of neuroradiology at the University Hospital and Faculty of Medicine of Bordeaux, and a senior researcher at the Institute of Neurodegenerative Diseases (IMN, CNRS, CEA, University of Bordeaux).

His current research focuses on the quantification of the sources of variability in brain morphology and function, and on the identification of early MRI markers of cerebral ageing, thanks to population neuroimaging combining MRI, psychometry and genomics. Bernard Mazoyer graduated from the Ecole Normale Supérieure de Cachan (mathematics, 1972-1976), holds a doctorate in biomathematics (1983) and medicine (1985) from the University of Paris. He did a post-doctorate at the Lawrence Berkeley Lab (USA) in the field of advanced medical imaging techniques, in particular PET and MRI (1984-1985).

He was then recruited by the French Atomic Energy Commission at the Orsay centre to direct the positron emission tomography programme and in particular the development of PET brain activation studies (1986-1990).

He was then elected Professor of Biostatistics and Medical Informatics at the CHU and at the Faculty of Medicine Paris 7 (1990-1997) while continuing to work with PET and MRI for the CEA.  In 1997, he moved to Caen as Professor of Radiology and Medical Imaging (1997-2012) and Director of the Cyceron multimodal biomedical imaging platform, which he will develop as a reference centre for translational imaging in the fields of neurology, cardiology and oncology. Since 2012, he is professor of neuroradiology at the Bordeaux University Hospital and senior researcher at the Institute of Neurodegenerative Diseases (CNRS, CEA, University of Bordeaux).

Bernard Mazoyer is a pioneer of brain imaging techniques and their applications to the study of the neural bases of cognitive functions under normal and pathological conditions. In 1989, he co-founded the GIN (http://www.gin.cnrs.fr/en/about-us/), the first cognitive neuroimaging team in France, of which he was director until 2016.  He is also one of the pioneers of population-based neuroimaging, which enables the study of cerebral ageing through the analysis of very large multimodal databases.

He organised the 1st Conference on Brain Mapping in 1995 in Paris and was at the origin of the creation in 1997 of the Organisation for the Mapping of the Human Brain, of which he was the first elected president. Co-author of more than 350 scientific publications, his work has received more than 25,000 citations. He was elected a member of the Institut Universitaire de France in 2001, and received the Seymour Cray Prize in intensive digital computing (1993) and the Dagnan-Bouveret Prize of the National Academy of Moral and Political Sciences (2003).

A. Bikfalvi

Andreas BIKFLAVI

Research Director, U1029 Inserm Center

Andreas Bikfalvi is an MD PhD with both scientific and clinical training. He is an exceptional class full Professor ("Professeur de Classe Exceptionnelle") and leads since more than 20 years a laboratory that is affiliated to INSERM and the University of Bordeaux (now Angiogenesis and Tumor Microenvironment Laboratory, INSERM U1029).

His main line of research is related to vascular biology (angiogenesis) and tumour biology, focusing on studies dealing with angiogenesis and with the cross talk between angiogenesis and tumour biology and, in particular, metastasis. He has  also developed unique in vivo models allowing large-scale genomic approaches and is also focused on mechanistical studies involving key players.

Besides, he is also working on specific aspects of developmental angiogenesis and has developed unique in vitro models based on artificial blood vessels which can be used for mechanistically and pharmacological studies.